UnitedHealth Group has spent the past nine months telling investors its turnaround is ahead of schedule, raising its full-year outlook at every turn. The stock market has stopped listening. Shares have fallen about 17% since the company's last report even as the S&P 500 edged higher, leaving the managed-care giant roughly 20 percentage points behind the broader market. When UnitedHealth reports before the open on October 13, the question is less whether it can clear a modest bar and more whether it can persuade a skeptical market that its improving Medicare story outweighs a commercial business that keeps getting worse.

Wall Street expects adjusted earnings of $4.12 per share, a 41% jump from the $2.92 earned a year ago, on revenue of about $111.4 billion, down 1.6%. That combination tells the story of this recovery: shrinking revenue as the company sheds unprofitable Medicare Advantage members, paired with sharply better margins. The whisper number of $4.60 sits meaningfully above consensus, suggesting the informal bar is higher than published estimates imply. That makes sense given management's guidance. Last quarter it lifted its 2026 adjusted EPS target to $19.50 to $20.00, up from a prior floor of $18.25 and an initial floor of $17.75. The full-year consensus at the time of that raise was $18.39, well short of the new range, so analysts may still be catching up. A third-quarter figure near the whisper would help close that gap; a print near consensus could leave investors wondering whether the second quarter's $6.38 was a high-water mark.

The bull case rests on Medicare Advantage. Management now expects margins in that business to finish above 3%, a far cry from the roughly half-point improvement it framed at the start of the year, helped by medical cost trend running below its initial 10% assumption. It also narrowed its expected membership loss to about 1.1 million and tightened the full-year medical care ratio to 88.1%, plus or minus a quarter point. This report needs to show that ratio holding. Because last quarter's improvement leaned partly on a mild respiratory season and favorable prior-year development, a third quarter in which Medicare costs stay contained without those tailwinds would go a long way toward proving the gains are structural rather than lucky.

The bear case lives in commercial insurance. Cost trend there has climbed from about 11% to modestly above that level and is still rising, which management attributed to arbitration payouts under the No Surprises Act and more aggressive provider coding. Perhaps most damaging, the company pushed its target for restoring commercial margins to 7% or better beyond 2027. Any sign that the trend is stabilizing would be welcome; further deterioration, or another delay, would reinforce the idea that UnitedHealth is trading one problem for another. Medicaid, guided to negative margins this year as rate increases lag costs, remains a secondary drag worth checking.

Optum offers supporting evidence. OptumHealth's operating earnings target was raised to at least $2.2 billion on the back of fewer hospitalizations and skilled nursing admissions, and the company is pushing AI tools for prior authorization and clinical documentation. Progress on those fronts, along with the buyback that was doubled to at least $5 billion, would support management's claim that 13% to 16% long-term growth is achievable from the 2026 base.

Sentiment has soured, swinging from barely bullish before the last report to about 14% bearish now. The stock trades near $372, just 2.5% above its post-earnings low of $362.60 and modestly above its 200-day moving average, far from the $461.62 high reached after the last report. That positioning lowers the emotional bar, but it also signals deep doubt. Ultimately, the report will turn on whether Medicare strength looks durable enough, and commercial pressure contained enough, for the raised 2026 range to look conservative rather than optimistic.